Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India

Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India

Abstract Background Cytokine storm triggered by Severe Coronavirus Disease 2019 (COVID-19) is associated with high mortality. With high Interleukin -6 (IL-6) levels reported in COVID-19 related deaths in China, IL-6 is considered to be the key player in COVID-19 cytokine storm. Tocilizumab, a monocl...

Full description

Bibliographic Details
Main Authors: Yojana Gokhale, Rakshita Mehta, Uday Kulkarni, Nitin Karnik, Sushant Gokhale, Uma Sundar, Swati Chavan, Akshay Kor, Sonal Thakur, Trupti Trivedi, Naveen Kumar, Sujata Baveja, Aniket Wadal, Shaonak Kolte, Aukshan Deolankar, Sangeeta Pednekar, Lalana Kalekar, Rupal Padiyar, Charulata Londhe, Pramod Darole, Sujata Pol, Seema Bansode Gokhe, Namita Padwal, Dharmendra Pandey, Dhirendra Yadav, Anagha Joshi, Harshal Badgujar, Mayuri Trivedi, Priyanshu Shah, Prerna Bhavsar
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Infectious Diseases
Subjects:
IL-6
Interlukin-6
Cytokine storm
Hyperinflammatory syndrome
CO-RADS
CT-severity score
Online Access:https://doi.org/10.1186/s12879-021-05912-3

Internet

https://doi.org/10.1186/s12879-021-05912-3

Similar Items